Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 1/20 | 0.43 |
| ▸ | F9 | P00740 | 10/20 | 0.40 |
| ▸ | CFTR | P13569 | 1/20 | 0.35 |
| ▸ | NMBR | P28336 | 4/20 | 0.34 |
| ▸ | GHSR | Q92847 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17999310 | 1.00 | TACR1 (0.43) | TACR1F9CFTRNMBRGHSR | |
| SCHEMBL17999521 | 0.92 | F9 (0.42) | TACR1F9CFTRNMBRGHSR | |
| SCHEMBL17999520 | 0.92 | F9 (0.42) | TACR1F9CFTRNMBRGHSR | |
| SCHEMBL29547755 | 0.90 | F9 (0.40) | TACR1F9CFTRNMBRGHSR | |
| SCHEMBL29548267 | 0.89 | F9 (0.40) | TACR1F9CFTRNMBRGHSR | |
| SCHEMBL29547959 | 0.84 | TACR1 (0.38) | TACR1F9NMBRGHSR | |
| SCHEMBL5881032 | 0.79 | TACR1 (0.51) | TACR1NMBRGHSRLMNABAZ2B | |
| SCHEMBL24461333 | 0.78 | TACR1 (0.38) | TACR1NMBRGHSRLMNA | |
| SCHEMBL29619411 | 0.78 | TACR1 (0.38) | TACR1NMBRGHSRLMNA | |
| SCHEMBL17999457 | 0.76 | F9 (0.45) | TACR1F9CFTRNMBRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3258929-B1 | FACTOR IXA INHIBITORS | MERCK SHARP & DOHME (US) | 2022-04-27 | — | — | EP | disclosed |
| US-10351558-B2 | Factor IXa inhibitors | MERCK SHARP & DOHME CORP. (US) | 2019-07-16 | — | — | US | disclosed |
| US-20180022747-A1 | Factor IXa Inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-01-25 | — | — | US | disclosed |
| EP-3258929-A1 | FACTOR IXa INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2017-12-27 | — | — | EP | disclosed |
| WO-2016133793-A1 | FACTOR IXa INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180022747-A1 | Factor IXa Inhibitors | F9, TFPI, F12 | TACR1 2148/4885F9 1/4885CFTR 1583/4885 |
| US-10351558-B2 | Factor IXa inhibitors | F9, TFPI, F12 | TACR1 2148/4885F9 1/4885CFTR 1583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.